Grifols Announces the Appointment of Thomas Glanzmann as Chairman of its New Board of Directors for U.S. Operations

By Grifols, PRNE
Sunday, June 5, 2011

RESEARCH TRIANGLE PARK, North Carolina, June 6, 2011 -

- Following the recent acquisition of Talecris Biotherapeutics, Grifols
has established a new Board of Directors for its US operations that draws on
some of industry's most well-known and experienced leaders, who will assure a
smooth integration of the two companies and create a new leader in the plasma
therapies market.

(NASDAQ: GRFS). Grifols, a global healthcare company and
biopharmaceutical manufacturer based in Barcelona, Spain, today announced the
establishment of a new Board of Directors for its U.S. operations, including
the appointment of Thomas Glanzmann as Chairman of the Board, who previously
was president of another leading global plasma therapeutics business, and the
reappointment of Gregory Rich as Chief Executive Officer (CEO) of Grifols
U.S. operations.

(Logo: )

Thomas Glanzmann was also appointed to direct the integration process
because of his past leadership experience in the plasma industry and his
history of successfully integrating other companies with plasma product

"It is an honor to serve in this capacity and with such an experienced
group of professionals," said Thomas Glanzmann. "I look forward to bringing
together the outstanding expertise of these two successful companies to
create the world's leading plasma company," Mr. Glanzmann said. With the
transaction now complete, Grifols will begin the process of integrating the
two companies.

Gregory Rich will continue as CEO of Grifols' expanded U.S. operations
that now include manufacturing facilities and corporate offices in North
. "Our enlarged presence in the U.S. will provide tremendous
opportunities for us to expand patient access to plasma therapies both
domestically and around the world," stated Mr. Rich. "As we integrate our two
companies into one, our goal is to build on the exceptional customer service
and quality operations that people have come to expect from both Grifols and
Talecris," said Mr. Rich. With more than thirty years of experience in the
plasma industry associated with Grifols, Mr. Rich has driven Grifols'
profitability in the U.S., serving as CEO of the US operations since 2003.
The combined 2010 U.S. sales for both companies were more than $1.8 billion.

"The combined experience of this Board is unsurpassed in the plasma
industry," said Mr. Victor Grifols, President of Grifols, S.A., the parent
holding company of Grifols U.S. operations. "The continuity of leadership and
oversight from this Board of Directors will assure a successful integration
and position us for tremendous growth," continued Mr. Grifols. The new
eight-member Board of Directors is composed of individuals with unparalleled
experience and proven capabilities, many of whom also serve on the Board of
Directors for Grifols, S.A.

In addition to Messrs Glanzmann and Rich, the Board members include:

    - Víctor Grifols, President of the Board of Directors for Grifols, S.A.,
      the Spanish holding company, since 1991, has nearly 40 years of
      experience in the industry. Since becoming Chairman, Mr. Grifols has
      grown the company from under $200 MM in revenue in 1991 to nearly $1.5
      billion in 2010, prior to acquiring Talecris.

    - Juan Ignacio Twose has served as Grifols' Vice President of
      Manufacturing since 1988. Mr. Twose joined Grifols 1973 as a director
      and has been responsible for the industrial division of Grifols since
      its creation. He has overseen the company's strategic growth and
      development of production facilities and infrastructure investment. Mr.
      Twose received a degree in industrial engineering from the Escuela
      Tecnica Superior of Barcelona.

    - Ramon Riera serves as Grifols' Vice President of Global Marketing and
      Sales and has been with Grifols since 1977. In 1988 Mr. Riera became
      the Vice President of Marketing and Sales worldwide. He has been
      responsible for leading the company's strategic international growth
      and establishing Grifols as a global healthcare company. Mr. Riera
      earned a degree in chemical sciences from the Universidad Autonoma de

    - Alfredo Arroyo, Vice President of Finances and Chief Financial Officer,
      has been with Grifols for more than 4 years. Prior to joining Grifols,
      Mr. Arroyo served in different senior financial positions for a variety
      of international companies. In his role on the Board, Mr. Arroyo will
      facilitate the Talecris integration process by identifying and
      capturing synergies resulting from the combination of the two

    - David I. Bell, General Counsel and Vice President of Corporate
      Operations and Development, joined Grifols when the company entered the
      U.S. market in 2003. Prior to joining Grifols, Mr. Bell was general
      counsel to Alpha Therapeutic Corporation following a 23-year career as
      a corporate litigator. Mr. Bell played an integral role in Grifols'
      acquisition of Talecris and has been instrumental in other Grifols
      acquisitions in the U.S.

    - Tomas Daga has served as a director of Grifols since April 2000 and has
      led the company's mergers and acquisitions growth strategy, including
      the recent Talecris acquisition. He is also a member of the Board of
      Directors of Scranton Enterprises B.V., Zambon, S.A., Pharmazam S.A.
      and StoraEnso Barcelona, S.A. Mr. Daga is a trustee of the Joaquim
      Molins Figueras Foundation in Barcelona and is the managing partner of
      the Barcelona office of the law firm Osborne Clarke Spain. Prior to
      joining Osborne Clarke, Mr. Daga worked in the corporate and tax
      department of Peat Marwick Mitchell & Co. in Barcelona from December
      1979 to September 1986. Mr. Daga earned a law degree from the
      University of Barcelona.

    - Raimon Grifols is an ex-officio member of the Board serving as
      Secretary since 2001. He is a partner at the law firm of Osborne Clarke
      Spain and a member of the Board of Directors of Squadron Reinsurance
      Ltd., Marca Grifols, S.L., Arrahona Optimus, S.L., and patron of the
      Probitas Fundacion Privada. Mr. Grifols earned his law degree from the
      University of Barcelona.

Additional seats on the Board of Directors for Grifols U.S. operations
will be considered as the integration progresses. The new Board of Directors
for U.S. operations is fully empanelled and has assumed operational oversight
of Grifols U.S. operations, including Talecris. The entire U.S. Board of
Directors is meeting in Raleigh, NC, during the first part of June 2011 to
formally launch the Talecris integration process.

About Grifols

Grifols is a Spanish holding company that specializes in the
pharmaceutical-hospital sector and is present in more than 90 countries. The
company's class A shares have been listed on the Spanish Stock Exchange
("Mercado Continuo") since 2006 under the symbol GRF and have been part of
the Ibex-35 since 2008. In 2011, the company listed non-voting class B shares
on the Mercado Continuo under the symbol GRF.P and in the United States on
the NASDAQ under the symbol GRFS.

After the recent purchase of Talecris, Grifols is now the third largest
company worldwide in the plasma protein therapies sector, with a balanced and
diversified range of products. In upcoming years, the company will strengthen
its leadership in the industry as a vertically integrated company, as a
result of ongoing investment plans. Grifols is the world leader in plasma
collection, with 147 plasma donor centers in the United States to ensure a
continued and reliable supply of human plasma for the production of plasma
therapies. In terms of production capacity (fractionation), Grifols owns and
operates several plants in Spain and the United States that allow the company
to respond to the growing market demand. Grifols' sustained growth will be
supported by a strong presence in the United States, Canada and Europe, where
upcoming sales will represent 53%, 7% and 26%, respectively.


The facts and figures contained in this report which do not refer to
historical data are "projections and forward-looking statements". The words
and expressions like "believe", "hope", "anticipate", "predict", "expect",
"intend", "should", "try to achieve", "estimate", "future" and similar
expressions, insofar as they are related to Grifols Group, are used to
identify projections and forward-looking statements. These expressions
reflect the assumptions, hypothesis, expectations and anticipations of the
management team at the date of preparation of this report, which are subject
to a number of factors that could make the real results differ considerably.
The future results of Grifols Group could be affected by events related to
its own activity, such as shortages of raw materials for the manufacture of
its products, the launch of competitive products or changes in the
regulations of markets in which it operates, among others. At the date of
preparation of this report Grifols Group has adopted the measures it
considers necessary to offset the possible effects of these events. Grifols,
S.A. does not assume any obligation to publicly inform, review or update any
projections and forward-looking statements to adapt them to facts or
circumstances following the preparation of this report, except as
specifically required by law.

This document does not constitute an offer or invitation to purchase or
subscribe shares, in accordance with the provisions of the Spanish Securities
Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11,
and/or Royal Decree 1310/2005, of November 4, and its implementing

Media, In the US: Chris Healey, +1-202-302-2521, or Outside the US: Raquel Lumbreras, +34-659-57-21-85, or Borja Gomez, +34-650-40-22-25, Grifols' press office (Spain), or Investor Relations, Nuria Pascual or Olga Santos, of Grifols, SA, + 34-93-571-0221

will not be displayed